RTI Surgical Holdings Inc

RTI Surgical — Regeneration Technologies — ROTH Growth Stock Conference 2008

27 slides from RTI Surgical's conference presentation, Feb 19, 2008

  1. Slide 1: Tutogen Medical, Inc. ROTH Growth Stock Conference

    Slide 1: Tutogen Medical, Inc. ROTH Growth Stock Conference

    Tutogen Medical, Inc. ROTH Growth Stock Conference February 2008 AMEX: TTG

  2. Slide 2: Forward Looking Statement

    Slide 2: Forward Looking Statement

    FORWARD LOOKING STATEMENT This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements about the expected benefits of the business combination involving Regeneration Tech

  3. Slide 3: About the Transaction

    Slide 3: About the Transaction

    ABOUT THE TRANSACTION Terms of the deal: Tax-free, stock-for-stock exchange Tutogen shareholders will receive 1.22 shares of newly issued RTI common stock in exchange for each share of Tutogen common stock they own Expect to close in Q1 2008, subject to regulatory and other customary conditions Pro

  4. Slide 4: Combined Leadership

    Slide 4: Combined Leadership

    COMBINED LEADERSHIP Executive Leadership: Brian Hutchison, Chairman and CEO Guy Mayer, President – focused on international activities and sales and marketing Tom Rose, VP, CFO and Secretary Bob Johnston, VP Finance Board of Directors: Total of 12 directors – Seven directors from RTI board, includin

  5. Slide 5: Implant Segments

    Slide 5: Implant Segments

    IMPLANT SEGMENTS Int'l 6% Spine 43% Other 26% Sports Med 25% Int'l 28% Dent. 48% Spine 10% Other 14% Other 6% Spine 32% Dental 17% Int'l 14% Surgical Spec 5% BGS 10% Sports Med 16% + RTI Tutogen Combined Company

  6. Slide 6: Combined Implant Segments

    Slide 6: Combined Implant Segments

    COMBINED IMPLANT SEGMENTS RTI Tutogen Combined Spine Sports Medicine Bone Graft Substitutes General Orthopedic Other Dental Urology Hernia Ophthalmology Breast Reconstruction ENT International

  7. Slide 7: Combined Financial Highlights

    Slide 7: Combined Financial Highlights

    COMBINED FINANCIAL HIGHLIGHTS >$30 million in cash at Dec. 31, 2007 and generate positive operating cash flow Strong balance sheet with very little debt Accretive to RTI’s 2008 GAAP earnings per share $5-6MM of identified 2008 cost savings when fully implemented Significant revenue enhancement oppor

  8. Slide 8: Combined Revenue

    Slide 8: Combined Revenue

    COMBINED REVENUE Tutogen and RTI Revenue Comparison Calendar Year 2007 vs. 2006 31.4% 32.4% 34.7% 30.8% 27.2% Revenue Growth $36,172 $9,902 $10,035 $8,743 $7,492 Revenue Growth $115,346 $30,554 $28,909 $28,343 $2,750 $151,518 $40,456 $38,944 $37,086 $3,502 Combined Revenue: Total Q4 Q3 Q2 Q1 Calenda

  9. Slide 9: Tutogen is a leading worldwide manufacturer and supplier

    Slide 9: Tutogen is a leading worldwide manufacturer and supplier

    Tutogen is a leading worldwide manufacturer and supplier of sterile biological implants made from human (allograft) and animal (xenograft) soft tissue and bone The Company is the only biologics manufacturer worldwide able to claim a 100% sterile full product complement using the Company’s Tutoplast

  10. Slide 10: Tutoplast Process Production Flow

    Slide 10: Tutoplast Process Production Flow

    Multi-step Process Substantially eliminates all types of pathogens More than 1.5 million grafts implanted With an unblemished 30 year safety record Tutoplast ® Process Production Flow DELIPIDIZATION OSMOTIC TREATMENT OXIDATIVE TREATMENT DEHYDRATION TISSUE DONATION PRECISION MACHINING STERILIZATION I

  11. Slide 11: Advantages of Tutoplast Process

    Slide 11: Advantages of Tutoplast Process

    Advantages of Tutoplast Process Inactivates and removes bacteria Removes lipids Inactivates prion activity Removes antigenicity Eliminates viral infectivity by a safety margin of 5 log (100,000 times) Breaks down RNA and DNA into fragments not capable of replication and disease transmission Preserve

  12. Slide 12: U.S. Addressable Markets

    Slide 12: U.S. Addressable Markets

    Spine, $656 Dental, $174 Surgical Specialty, $279 U.S. Market Size: $1.25 Billion* Addressable Markets Hernia $150 Urology Obstetrics/Gynecology Breast Reconstruction Ophthalmology Ear Nose & Throat (ENT) *Source: Internal Estimates and Orthopedic Network News, October

  13. Slide 13: Dental Market Partnership: Zimmer Dental

    Slide 13: Dental Market Partnership: Zimmer Dental

    Partnership – Zimmer Dental, Inc. - subsidiary of Zimmer Holdings (NYSE: ZMH) – Valued partner since Sept. 2000 – Worldwide – New Agreement Completed August 2007 Products and Applications – Puros Block Allograft increases bone volume for surgical ridge augmentation – Puros Cortical Particulate Allog

  14. Slide 14: U.S. Quarterly Dental Sales

    Slide 14: U.S. Quarterly Dental Sales

    U.S. Quarterly Dental Sales (Jan. 2002 to December 2007) Quarterly Dental Sales $0 $1,000 $2,000 $3,000 $4,000 $5,000 $6,000 $7,000 $8,000 Good market growth – Puros Bone at about a 20% market share • Strong brand recognition • Good clinical outcomes • Zimmer educational forums • Support from opinio

  15. Slide 15: Dental Accounts Growth

    Slide 15: Dental Accounts Growth

    Dental Accounts Growth – Past 18 Months

  16. Slide 16: International Dental Opportunity

    Slide 16: International Dental Opportunity

    International Dental Opportunity Total Market-$180 million Several regulatory approvals already in place Exclusive Distributorship in over 30 countries including Germany-large dental implant market-large potential Full line of allograft and xenograft products to promote bone growth for dental implan

  17. Slide 17: Spine Market

    Slide 17: Spine Market

    Allograft Bone 19% Spine Market Estimated 2005 U.S. Machined Bone Market – $321 Million, 18% growth* Estimated percent of time bone is used in Spinal fusion procedures – ALIF – 12% – Cervical – 68% – PLIF – 72% – TLIF – 9% Current Focus on Machined Bone – New Products shipped to Zimmer • Puros C for

  18. Slide 18: Spine Market Partnership: Zimmer Spine

    Slide 18: Spine Market Partnership: Zimmer Spine

    Partnership – Zimmer Spine, Inc. - subsidiary of Zimmer Holdings (NYSE: ZMH) – Valued partner since Sept. 2000 – U.S. & Canada Products and Applications – Puros Bone for enhancing interbody fusion • Traditional bone • Specialty Machined grafts – Cervical Grafts, ALIF and PLIF Initiatives – First new

  19. Slide 19: Hernia Market Partnership: Davol

    Slide 19: Hernia Market Partnership: Davol

    NEW Partnership – Davol Inc. – subsidiary of CR Bard, Inc. (NYSE: BCR) – Market leader (60%) in estimated $500 million worldwide market Products and Applications – Repair of hernias and reconstruction of the chest and abdominal walls – AlloMax-human dermis product Initiatives – Training sales force

  20. Slide 20: Breast Reconstruction Partnership: Mentor

    Slide 20: Breast Reconstruction Partnership: Mentor

    Breast Reconstruction NEW Partnership – Mentor Corporation (NYSE: MNT) – Market leader in Breast Implants Applications and Products – Breast Reconstruction following Mastectomy – NeoForm™ Human Dermis Initiatives – Training sales force – Product introduced in 2 nd Quarter to clinical sites – Product

  21. Slide 21: International Business

    Slide 21: International Business

    International Business Projected Sales Mix, by specialty Membranes 36% Orthopaedic 35% Sports Medicine 3% Tissue Service 10% Dental 16% Distributor Based Sales – 60% Membranes / 40% Bone – 65% Human / 35% Bovine Strategy Driving Global Agreements – Davol Hernia Repair Signed January 2006 – Coloplast

  22. Slide 22: Bovine Initiatives

    Slide 22: Bovine Initiatives

    Bovine Initiatives 30%-35% of international sales are bovine products Tutogen to introduce bovine pericardium product to U.S. marketplace through Zimmer Dental-January 2008 Tutogen to introduce bovine pericardium product for hernia repair in U.S. to initial clinical sites over the next 12 months Col

  23. Slide 23: Revenues for Years Ended September 30, 2007 and 2006

    Slide 23: Revenues for Years Ended September 30, 2007 and 2006

    Revenues for Years Ended September 30, 2007 and 2006 (in 000’s) Years Ended September 30, % Change Dental $24,329 $17,616 38% Spine $5,516 $2,877 92% Surgical Specialties $8,139 $4,937 65% Total U.S. Revenues $37,984 $25,430 49% International Revenues $15,835 $12,517 27% Total Consolidated Revenues

  24. Slide 24: Revenues for Quarters Ended December 31, 2007 and 2006

    Slide 24: Revenues for Quarters Ended December 31, 2007 and 2006

    Revenues for Quarters Ended December 31, 2007 and 2006 (in 000’s) Quarters Ended December 31, % Change Dental $6,720 $5,286 27% Spine $1,150 $1,293 -11% Surgical Specialties $2,683 $1,554 73% Total U.S. Revenues $10,553 $8,133 30% International Revenues $4,402 $3,330 32% Total Consolidated Revenues

  25. Slide 25: Quarterly Financials

    Slide 25: Quarterly Financials

    Quarterly Financials $11.5 $13.0 $14.2 $15.2 $15.0 $0 $2 $4 $6 $8 $10 $12 $14 $16 Dec. '06 Mar. '07 June '07 Sep. '07 Dec. '07 Revenue Net Income * Includes $1.6million in costs related to the proposed merger. Excluding these costs, the company would have generated a $343K profit or a $.02 per share

  26. Slide 26: Balance Sheet as of December 31, 2007

    Slide 26: Balance Sheet as of December 31, 2007

    Balance Sheet as of December 31, 2007 Cash $11.1M Accounts Receivable $7.5M Inventory $19.0M Other $4.3M Total Current Assets $41.9M Total Assets $59.8M Total Current Liabilities $13.8M Long Term Debt $3.2M Other $2.5M Total Liabilities $19.5M Total Shareholders' Equity $40.3M Total Liabilities & Sh

  27. Slide 27: Tutogen Medical, Inc.

    Slide 27: Tutogen Medical, Inc.

    Tutogen Medical, Inc. ROTH Growth Stock Conference February 2008 AMEX: TTG

Source: SEC EDGAR · 425 filed Feb 19, 2008

More decks from RTI Surgical Holdings Inc